COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA and MYELODYSPLASTIC SYNDROME
AssigneeBoehringer Ingelheim International GmbH
InventorsTillmann TAUBE, Dorothea RUDOLPH
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Claims15
A method of treating a patient suffering from myeloid leukemia (AML) and/or myelodysplastic syndrome (MDS), comprising:
- administering to the patient Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof, and Quizartinib or a pharmaceutically acceptable salt thereof or a hydrate thereof, wherein the Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof and Quizartinib or a pharmaceutically acceptable salt thereof or a hydrate thereof are administered simultaneously, separately or sequentially.
A pharmaceutical composition comprising an effective amount of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof, and an effective amount of Quizartinib or a pharmaceutically acceptable salt thereof or a hydrate thereof.
A pharmaceutical combination comprising Volasertibor a pharmaceutically acceptable salt thereof or a hydrate thereof, and Quizartinib or a pharmaceutically acceptable salt thereof or a hydrate thereof, for simultaneous, separate or sequential administration to and treatment of a patient suffering from AML and/or MDS.
Dependencies are inferred from the claim text.